Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity

The Journal of Infectious Diseases
Nathan P WiederholdRussell E Lewis

Abstract

A paucity of data exists regarding the pharmacodynamics of caspofungin (CAS) during invasive pulmonary aspergillosis (IPA). We conducted a dosage-fractionation study to characterize the in vivo pharmacodynamics of CAS activity during IPA, using immunosuppressed mice inoculated intranasally with Aspergillus fumigatus. After single intraperitoneal doses (0.25, 1.0, and 4.0 mg/kg), plasma CAS concentrations were assayed by high-performance liquid chromatography. The pharmacokinetic data were analyzed by nonparametric population pharmacokinetic analysis. Three dosage groups (0.25, 1.0, and 4.0 mg/kg) fractionated into 3 different dosing intervals (q6, q24, or q48 h) were then used to evaluate the pharmacokinetic/pharmacodynamic effects (percentage of time greater than the minimum effective concentration [MEC], 96-h area under the plasma concentration curve:MEC ratio, and peak concentration in plasma [Cmax]:MEC ratio) at clinically achievable exposures. Mice were treated for 96 h and were then euthanized, and their lungs were harvested for analysis of pulmonary fungal burden by real-time quantitative polymerase chain reaction. A concentration-dependent reduction in mean pulmonary fungal burden was evident in mice in the 1 mg/kg dosa...Continue Reading

Citations

Nov 23, 2006·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·David GoldblumStefan Zimmerli
Jul 26, 2008·Medical Mycology·Russell E Lewis, Dimitrios P Kontoyiannis
Mar 4, 2009·Medical Mycology·Nathan P Wiederhold
Jan 11, 2013·The Journal of Infectious Diseases·Ronen Ben-AmiDimitrios P Kontoyiannis
Jul 29, 2008·The Journal of Antimicrobial Chemotherapy·Gabriela E BrzankalskiJohn R Graybill
Mar 26, 2010·The Journal of Antimicrobial Chemotherapy·Melanie W PoundRichard H Drew
Jul 23, 2008·Antimicrobial Agents and Chemotherapy·Maiken Cavling ArendrupCornelia Lass-Flörl
Jun 28, 2006·Antimicrobial Agents and Chemotherapy·Anthony CacciapuotiDavid Loebenberg
Dec 6, 2006·Antimicrobial Agents and Chemotherapy·Charalampos AntachopoulosThomas J Walsh
Dec 30, 2009·Antimicrobial Agents and Chemotherapy·Russell E LewisDimitrios P Kontoyiannis
Dec 15, 2010·Antimicrobial Agents and Chemotherapy·Enrique CalvoJosep Guarro
Dec 31, 2008·Antimicrobial Agents and Chemotherapy·Anthony M NicasioJoseph L Kuti
Apr 14, 2010·Antimicrobial Agents and Chemotherapy·D AndesA Lepak
May 5, 2010·Antimicrobial Agents and Chemotherapy·Thomas J WalshJohn E Conte
Apr 20, 2011·Antimicrobial Agents and Chemotherapy·Nathan P WiederholdThomas F Patterson
May 31, 2012·Antimicrobial Agents and Chemotherapy·Silvia MorettiFranco Aversa
Sep 29, 2005·Antimicrobial Agents and Chemotherapy·D T A te DorsthorstJ W Mouton
Oct 28, 2005·Antimicrobial Agents and Chemotherapy·Thomas J WalshNicholas A Kartsonis
Aug 30, 2005·Antimicrobial Agents and Chemotherapy·Donna M MacCallumFrank C Odds
Jan 16, 2007·Clinical Microbiology Reviews·M A Pfaller, D J Diekema

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.